FTRE: Fortrea Corp EV/EBITDA Multiple

Symbol and logo of brand Fortrea (FTRE)

Fortrea Holdings Inc. is expanding its laboratory network, increasing profitability through digital data collection. Production capacities are fully utilized as the company undergoes a modernization phase of its diagnostic equipment. Test efficiency is improving through the implementation of AI platforms for biodata processing. Reviewing the EV/EBITDA valuation dynamics on GURU.Markets, it is evident that 22.88 is recorded as the baseline value for this key multiple.

FTRE Fortrea Clinical: Total Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/17/2026

Analytical breakdowns for Fortrea Holdings Inc.

- stock price and consensus target price:
Fundamental valuation:FTRE (Fortrea Holdings Inc)
Original product of fortrea.com

To assess the long-term risks of Fortrea Holdings Inc. (FTRE), the enterprise value to EBITDA ratio is utilized, which accounts for debt load and capitalization. The EV/EBITDA trend for this capital-intensive business allows for a comparison of operational efficiency against the market price of assets, which is critical given the saturation of the early-stage research segment in the US and the dependence on long-term pharmaceutical contracts.